Neuphoria Therapeutics Inc 6-K, filed Aug 8, 2022
Neuphoria Therapeutics Inc. (NEUP)
About this 6-K
Neuphoria Therapeutics Inc filed this 6-K on August 8, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2022
(Commission File No. 001-41157)
BIONOMICS LIMITED
(Translation of registrant’s name into English)
200 Greenhill Road
Eastwood SA 5063
Tel: +618 8150 7400
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On August 8, 2022, Bionomics Limited (the “Company”) lodged a press release with the Australian Securities Exchange (the “ASX”), announcing that it had received A$2,085,453.17 research and development (R&D) tax incentive refund relating to the financial year ended June 2021. The press release is furnished herewith as Exhibit 99.1 to this report on Form 6-K.
1
EXHIBIT INDEX
|
|
Exhibit
|
Description
|
99.1 |
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M |
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
Bionomics Limited |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Errol De Souza
|
|
Name: |
Errol De Souza, Ph.D. |
|
Title: |
Executive Chairman |
Date: August 8, 2022
3
Exhibit 99.1
ABN 53 075 582 740
ASX ANNOUNCEMENT
8 August 2022
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development (R&D) tax incentive refund relating to the financial year ended June 2021.
The Australian Government R&D tax incentive encourages companies to engage in R&D benefiting Australia, by providing a tax offset of up to 43.5% (refundable) for eligible R&D activities.
Released on authority of the Executive Chairman.
FOR FURTHER INFORMATION PLEASE CONTACT:
General: Ms Suzanne Irwin Company Secretary +61 8 8150 7400 CoSec@bionomics.com.au
|
Investor Relations: Mr. Connor Bernstein Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au |
|||
|
|
|
|
|
About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
www.bionomics.com.au
Factors Affecting Future Performance
This announcement contains “forward-looking” statements within the meaning of the U.S. federal securities laws. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements related to the Offering are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.